209 related articles for article (PubMed ID: 36067171)
21. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells.
Zikry TM; Wolff SC; Ranek JS; Davis HM; Naugle A; Luthra N; Whitman AA; Kedziora KM; Stallaert W; Kosorok MR; Spanheimer PM; Purvis JE
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2309261121. PubMed ID: 38324568
[TBL] [Abstract][Full Text] [Related]
23. Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib.
Ji W; Shi Y; Wang X; He W; Tang L; Tian S; Jiang H; Shu Y; Guan X
Int J Biol Sci; 2019; 15(3):522-532. PubMed ID: 30745839
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
Zhang G; Ma F; Li L; Li J; Li P; Zeng S; Sun H; Li E
Biochem Pharmacol; 2019 May; 163():133-141. PubMed ID: 30772267
[TBL] [Abstract][Full Text] [Related]
25. Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Nomanbhoy TK; Sharma G; Brown H; Wu J; Aban A; Vogeti S; Alemayehu S; Sykes M; Rosenblum JS; Kozarich JW
Biochemistry; 2016 Sep; 55(38):5434-41. PubMed ID: 27571378
[TBL] [Abstract][Full Text] [Related]
26. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
28. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
29. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
[TBL] [Abstract][Full Text] [Related]
30. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
[TBL] [Abstract][Full Text] [Related]
31. Many Ways to the Cell Cycle Exit after Inhibition of CDK4/6.
Macůrek L
Folia Biol (Praha); 2023; 69(5-6):194-196. PubMed ID: 38583181
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
33. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
34. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
35. Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
Pandey K; Park N; Park KS; Hur J; Cho YB; Kang M; An HJ; Kim S; Hwang S; Moon YW
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260316
[TBL] [Abstract][Full Text] [Related]
36. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
37. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
[TBL] [Abstract][Full Text] [Related]
39. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
40. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
